CELLECTIS (ALCLS.PA) Stock Price & Overview
EPA:ALCLS • FR0010425595
The current stock price of ALCLS.PA is 3.21 EUR. Today ALCLS.PA is down by -5.59%. In the past month the price increased by 0.31%. In the past year, price increased by 155.57%.
ALCLS.PA Key Statistics
- Market Cap
- 322.044M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.28
- Dividend Yield
- N/A
ALCLS.PA Stock Performance
ALCLS.PA Stock Chart
ALCLS.PA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ALCLS.PA. When comparing the yearly performance of all stocks, ALCLS.PA is one of the better performing stocks in the market, outperforming 96.92% of all stocks.
ALCLS.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA. Both the profitability and financial health of ALCLS.PA have multiple concerns.
ALCLS.PA Earnings
On November 7, 2025 ALCLS.PA reported an EPS of 0.01 and a revenue of 37.16M. The company beat EPS expectations (103.5% surprise) and beat revenue expectations (422.92% surprise).
ALCLS.PA Forecast & Estimates
13 analysts have analysed ALCLS.PA and the average price target is 6.63 EUR. This implies a price increase of 106.54% is expected in the next year compared to the current price of 3.21.
For the next year, analysts expect an EPS growth of -166.15% and a revenue growth 45.52% for ALCLS.PA
ALCLS.PA Groups
Sector & Classification
ALCLS.PA Financial Highlights
Over the last trailing twelve months ALCLS.PA reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 70.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.25% | ||
| ROE | -102.97% | ||
| Debt/Equity | 0.91 |
ALCLS.PA Ownership
ALCLS.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.02 | 39.989B | ||
| ARGX | ARGENX SE | 24.87 | 39.878B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.004B | ||
| ABVX | ABIVAX SA | N/A | 7.544B | ||
| 2X1 | ABIVAX SA | N/A | 7.536B | ||
| GXE | GALAPAGOS NV | N/A | 1.874B | ||
| GLPG | GALAPAGOS NV | N/A | 1.871B | ||
| NANO | NANOBIOTIX | N/A | 1.275B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.05B | ||
| PHIL | PHILOGEN SPA | 16.85 | 605.268M | ||
| GNFT | GENFIT | N/A | 423.775M | ||
| VLA | VALNEVA SE | N/A | 378.219M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALCLS.PA
Company Profile
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Company Info
CELLECTIS
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE FR
Employees: 219
Phone: 33181691600
CELLECTIS / ALCLS.PA FAQ
Can you describe the business of CELLECTIS?
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
What is the stock price of CELLECTIS today?
The current stock price of ALCLS.PA is 3.21 EUR. The price decreased by -5.59% in the last trading session.
Does ALCLS stock pay dividends?
ALCLS.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALCLS stock?
ALCLS.PA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for ALCLS stock?
The Revenue of CELLECTIS (ALCLS.PA) is expected to grow by 45.52% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is CELLECTIS worth?
CELLECTIS (ALCLS.PA) has a market capitalization of 322.04M EUR. This makes ALCLS.PA a Small Cap stock.